KRIPTON 2.5 bromocriptine 2.5mg (as mesilate) tablet bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

bromocriptine mesilate

Available from:

Alphapharm Pty Ltd

Authorization status:

Registered

Patient Information leaflet

KRIPTON
_contains the active ingredient bromocriptine (mesylate)_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Kripton.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking Kripton against
the benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT KRIPTON IS USED
FOR
Kripton contains the active ingredient
bromocriptine which belongs to a
group of medicines called ergot
alkaloids. Bromocriptine has an
effect on the body similar to that of a
chemical messenger occurring
naturally in the body called
dopamine.
Kripton has several uses that have
been outlined below.
•
Prevention of breast milk
production (lactation) in women
who cannot breastfeed for
medical reasons. If breast milk
production has already begun,
your doctor can advise you about
other methods of stopping
lactation.
•
Treatment of abnormally high
blood levels of a hormone called
prolactin. This condition is
sometimes caused by a tumour
called prolactinoma. Kripton can
be used alone or in combination
with surgery to treat this tumour.
•
Treatment of acromegaly, a
disease in which the body
produces too much growth
hormone. Kripton treats this
disease by reducing the excessive
amounts of growth hormone in
the blood.
•
Treatment of Parkinson's disease,
a condition where people
experience shaking (tremor),
muscle stiffness and slow and
unsteady body movements.
Kripton is often used in
combination with other medicines
such as levodopa to treat
Parkinson's disease.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY KRIPTON HAS
BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed
Kripton for another reason.
There is not enough information
available to recommend the use of
Kripton in children.
Kripton is availab

Summary of Product characteristics

KRIPTON
_Bromocriptine (mesylate) _
PRODUCT INFORMATION
NAME OF THE MEDICINE
Active ingredient
:
Bromocriptine mesylate
Chemical name
:
Ergotaman-3’,6’,18-trione,
2-bromo-12’-hydroxy-2’-(1-methylethyl)-5’- (2-
methylpropyl)-, (5’α)-;
2-Bromoergocryptine monomethanesulphonate;
2-bromo-α-ergocryptine
Structural formula
:
Molecular formula
:
C
32
H
40
BrN
5
O
5
CH
4
O
3
S
Molecular weight
:
750.7 (mesylate salt); 654.5
(free base)
CAS Registry no.
:
22260-51-1
DESCRIPTION
Bromocriptine mesylate is a peptide ergot alkaloid, poorly soluble in
water (<0.1% at 20-25

C). Freely soluble
in methanol. Solubility in ethanol (70% v/v) is 75%.
Kripton 2.5 tablets contains 2.5 mg of the active ingredient
bromocriptine mesylate and the following inactive
ingredients: lactose, starch-maize, silica-colloidal anhydrous, maleic
acid, disodium edetate and magnesium
stearate.
Kripton 5 and Kripton 10 capsules contain 5 mg and 10 mg,
respectively, of the active ingredient bromocriptine
mesylate. The capsules also contain the following inactive
ingredients: lactose, starch-maize, silica-colloidal
anhydrous, maleic acid, magnesium stearate, sodium lauryl sulfate,
gelatin, titanium dioxide, iron oxide black,
allura red AC, TekPrint SW-9008 Black Ink and TekPrint SW-9009 Black
Ink.
PHARMACOLOGY
Bromocriptine has a pharmacological spectrum unlike that of most
classical ergot compounds, having no
uterotonic and little vasoconstrictor activity. Its principal effects
derive from dopaminergic receptor stimulant
activity. It inhibits prolactin secretion and the effect can be
demonstrated after single or repeated oral
administration of the drug. Moreover, the effect is relatively
specific in that doses necessary to produce inhibition
of prolactin secretion do not interfere with release of gonadotrophins
or thyrotrophin. However, bromocriptine
elevates growth hormone for a few hours after each dose in normal or
diabetic persons. This may not be reflected
KRIPTON – Product Information
2
by an elevation of basal levels during chr